For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Imiquimod 5% Taro | Imiquimod 5% manufactured by Taro applied for 16 weeks | None | None | 4 | 183 | 22 | 183 | View |
| Aldara - Imiquimod 5% | Aldara, Imiquimod 5% applied for 16 weeks | None | None | 6 | 179 | 22 | 179 | View |
| Vehicle | Patients receiving imiquimod Vehicle for 16 weeks | None | None | 1 | 60 | 4 | 60 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| GASTROINTESTINAL HAEMORRHAGE | None | Gastrointestinal disorders | MedDRA (11.1) | View |
| HYPOTENSION | None | Vascular disorders | MedDRA (11.1) | View |
| NEPHROLITHIASIS | None | Renal and urinary disorders | MedDRA (11.1) | View |
| LOBAR PNEUMONIA | None | Infections and infestations | MedDRA (11.1) | View |
| TRANSIENT ISCHAEMIC ATTACK | None | Nervous system disorders | MedDRA (11.1) | View |
| CORONARY ARTERY OCCLUSION | None | Cardiac disorders | MedDRA (11.1) | View |
| ACUTE MYOCARDIAL INFARCTION | None | Cardiac disorders | MedDRA (11.1) | View |
| CEREBROVASCULAR ACCIDENT | None | Nervous system disorders | MedDRA (11.1) | View |
| DEHYDRATION | None | Metabolism and nutrition disorders | MedDRA (11.1) | View |
| SYNCOPE | None | Nervous system disorders | MedDRA (11.1) | View |
| NECK PAIN | None | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | View |
| OSTEOARTHRITIS | None | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| APPLICATION SITE PRURITUS | None | General disorders | MedDRA (11.1) | View |
| SQUAMOUS CELL CARCINOMA | None | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | View |
| APPLICATION SITE ERYTHEMA | None | General disorders | MedDRA (11.1) | View |
| APPLICATION SITE IRRITATION | None | General disorders | MedDRA (11.1) | View |